CareDx Inc., a precision medicine company, has entered a strategic collaboration with 10x Genomics, a leader in single cell and spatial biology, to establish ImmuneScape, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.

CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this initiative, which aim to generate high-resolution maps of the complex immune mechanisms underlying organ rejection associated with AMR and MVI. This data may help characterize disease origin and trajectory, as well as therapeutic response, laying the groundwork for future breakthroughs with potential to advance personalized transplant medicine.

What People are Saying

“This collaboration marks a meaningful step in advancing precision transplant care,” said John Hanna, President & CEO of CareDx. “By uniting CareDx’s clinical and diagnostic expertise with 10x Genomics’ transcriptomics technologies, we’re building upon a robust scientific foundation to drive future organ-health innovation across our diagnostic pipeline. Through ImmuneScape we aim to generate insights that translate transplant biology into high-value patient impact.”

“Despite extensive prior research, our understanding of the biology of transplant rejection remains incomplete,” said Serge Saxonov, Co-Founder and CEO of 10x Genomics. “By examining immune activity at the single cell level and within spatial context, this collaboration with CareDx opens a new window into the cellular and molecular signatures of rejection that have historically been impossible to measure. Together, we have the opportunity to generate insights with profound scientific impact – insights that have the potential to improve outcomes for transplant patients.”

ImmuneScape will build on CareDx’s ongoing efforts to deepen biological understanding in transplantation by mapping immune cell populations and pathways that distinguish mechanisms of disease origin and inform treatment selection, prognosis, and therapeutic response. CareDx recently introduced HistoMap Kidney, a tissue biopsy-based gene expression classifier designed to refine rejection subtyping and inform therapeutic management. The collaboration further extends this effort by examining how tissue-level immune architecture may correlate with clinical outcomes, including response to emerging therapies such as anti‑CD38 treatments.